
News|Articles|May 19, 2011
Sarcoma drug ridaforolimus may improve survival
LOS ANGELES (Reuters) - Ariad Pharmaceuticals' experimental cancer drug may improve overall survival in patients with advanced sarcoma, according to data from a phase III trial released Wednesday.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Biosimilar competition could surpass IRA-negotiated savings by year three
4
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
5





















































